Subclinical cardiac damage in cancer patients before chemotherapy
Heart Failure Reviews · 2022-07 · 27 (4) · 1091-1104
DOI: 10.1007/s10741-021-10151-4 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Heart Failure Reviews, online erschienen am 27.07.2021. Verfasst von Iacopo Fabiani und 10 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Division, Fondazione Toscana Gabriele Monasterio, Pisa, Italy. iacopofabiani@gmail.com. Hauptthemen laut MEDLINE: Heart Diseases, Heart Failure, Neoplasms, Ventricular Dysfunction, Left. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 152 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Scuola Superiore Sant'Anna.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Cancer and cardiovascular diseases, including heart failure (HF), are the main causes of death in Western countries. Several anticancer drugs and radiotherapy have adverse effects on the cardiovascular system, promoting left ventricular dysfunction and ultimately HF. Nonetheless, the relationship between cancer and HF is likely not unidirectional. Indeed, cancer and HF share common risk factors, and both have a bidirectional relationship with systemic inflammation, metabolic disturbances, and neurohormonal and immune activation. Few studies have assessed the impact of untreated cancer on the heart. The presence of an active cancer has been associated with elevated cardiac biomarkers, an initial impairment of left ventricular structure and function, autonomic dysfunction, and reduced exercise tolerance. In turn, these conditions might increase the risk of cardiac damage from chemotherapy and radiotherapy. HF drugs such as beta-blockers or inhibitors of the renin–angiotensin–aldosterone system might exert a protective effect on the heart even before the start of cancer therapies. In this review, we recapitulate the evidence of cardiac involvement in cancer patients naïve from chemotherapy and radiotherapy and no history of cardiac disease. We also focus on the perspectives for an early diagnosis and treatment to prevent the progression to cardiac dysfunction and clinical HF, and the potential benefits of cardioactive drugs on cancer progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cardiology Division, Fondazione Toscana Gabriele Monasterio, Pisa, Italy. iacopofabiani@gmail.com.
- Institute of Life Sciences, Scuola Superiore Sant'Anna, Pisa, Italy.
- Cardiology Division, Fondazione Toscana Gabriele Monasterio, Pisa, Italy.
- Internal Medicine Unit, University Hospital of Pisa, Pisa, Italy.
- Cardioncology Unit, Cardiology Division, European Institute of Oncology, I.R.C.C.S, Milan, Italy.
Förderung
- Scuola Superiore Sant'Anna
Zitieren
APA
Fabiani, I., Panichella, G., Aimo, A., Grigoratos, C., Vergaro, G., Pugliese, N. R., Taddei, S., Cardinale, D. M., Passino, C., Emdin, M., & Giannoni, A. (2022). Subclinical cardiac damage in cancer patients before chemotherapy. Heart Failure Reviews, 27(4), 1091-1104. https://doi.org/10.1007/s10741-021-10151-4
Vancouver
Fabiani I, Panichella G, Aimo A, Grigoratos C, Vergaro G, Pugliese NR, et al. Subclinical cardiac damage in cancer patients before chemotherapy. Heart Failure Reviews. 2022;27(4):1091-1104. doi:10.1007/s10741-021-10151-4
BibTeX
@article{Fabiani2022,
author = {Fabiani, Iacopo and Panichella, Giorgia and Aimo, Alberto and Grigoratos, Chrysanthos and Vergaro, Giuseppe and Pugliese, Nicola Riccardo and Taddei, Stefano and Cardinale, Daniela Maria and Passino, Claudio and Emdin, Michele and Giannoni, Alberto},
title = {Subclinical cardiac damage in cancer patients before chemotherapy},
journal = {Heart Failure Reviews},
year = {2022},
volume = {27},
number = {4},
pages = {1091--1104},
doi = {10.1007/s10741-021-10151-4}
}
EUVIMED